DEC 09, 2015 10:00 AM PST
WEBINAR: Emerging Trends in Heart Failure Therapy and the Importance of Natriuretic Peptides
SPONSORED BY: Roche Diagnostics
CONTINUING EDUCATION (CME/CE/CEU) CREDITS: CE
5 39 8693

Speakers:
  • Professor, Department of Pathology, Director of the Toxicology Laboratory, Associate Director of the Clinical Chemistry Lab, University of California, San Diego
    Biography
      Dr. Fitzgerald received his B.S. degree in Chemistry at Loyola College of Maryland and his Doctorate in Pharmacology/Toxicology at the Medical College of Virginia/Virginia Commonwealth University. After two and a half years as a forensic toxicologist for the State of Virginia, he took a position as the Director of the Mass Spectrometry Laboratory at the San Diego VA Hospital where he worked from 1992 until 2011.
      Currently Rob is a Professor in the Department of Pathology at the University of California, San Diego where he is the Director of the Toxicology Laboratory and Associate Director of the Clinical Chemistry Lab. He is board certified in toxicology and clinical chemistry by the American Board of Clinical Chemistry. Rob's teaching responsibilities include acting as the course chairmen for "Laboratory Medicine", a required course for 2nd year pharmacy students, and serving as the director of the pathology residency clinical chemistry program.

    Abstract:
    Date: December 9, 2015 10AM Pacific, 1PM Eastern

    July 7, 2015, the U.S. Food and Drug Administration reviewed and approved ENTRESTO™ (sacubitril/valsartan) tablets to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. This important news could shift the paradigm in the way heart failure patients will be managed using NT-proBNP in lieu of BNP for patients receiving ENTRESTO™.

    In this webinar, we will discuss the analytical and clinical considerations of NT-proBNP testing and the impact of ENTRESTO™ on biomarker testing.

    Learner Objectives:
     
    •             Describe differences in stability of NT-proBNP and BNP
    •             Describe the analytical differences between NT-proBNP and BNP assays
    •             Describe how natriuretic peptides compare in the setting of renal failure
    •             Describe the mechanism of action of ENTRESTO™ and it’s effect on natriuretic peptides

    Show Resources
    Loading Comments...